Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VOIS and ONCI both loading and preparing for AEG# style breakouts upwards!!
CCRY will be up on deck next week.
ONCI and VOIS both bottom plays ready to run.
VOIS and ONCI both getting ready for breakout.
"Debt holders won't have converted unless something is up". Exactly, that among other things have convinced me VOIS is ready to roll.
Momentum definitely building for VOIS. Buy in where you can, VOIS has a history of huge multiday, multi-bag runs.
I feel a PR is just around the corner, and its going to be big.
Or AEG#. Parabolic I would guess.
OR AEG# is my guess. Either way, about to get launched.
VOIS will be the next AEG#.
Definitely ONCI time.
Outstanding chart AE. If the fundamentals don't convince you (and they should) this chart certainly screams "Buy!!" at this point.
Gave them plenty of cash, and now we can expect zero dilution in near future, and certainly no R/S since that was completed and price has adjusted to both. Only upside here with positive progress reports expected. That is why the Institutions are rigously channeling this so they can load. So should we, I know I am have been.
Front-loading today. Fireworks very soon.
VOIS doing very well today, but the run is yet to come. This is a swing site, where we recommend buys that we see popping large within a couple weeks time.
Have to agree with you, I've seen this pattern many times and it is almost always followed by a huge run up the charts.
For a quality Big Board play, check out ATOS.
Atossa is a great patent play just for starters: Intellectual Property
We own five issued US patents and nine corresponding issued patents in Australia, Canada, Europe, Hong Kong, and Japan as well as pending patent applications in the US, Europe, and Japan. These patents have claims directed to a collection device for nipple aspirate fluid; for the method of making a diagnosis from NAF, using “whole cells, cell fragments, cell membranes, a protein, a peptide, a glycoprotein, a lipid, a glycolipid, a DNA polynucleotide, an RNA polynucleotide, or a combination thereof;” and the use of the drug oxytocin to increase the amount of NAF produced.
The patent and application numbers, by country, are:
United States United States: US Patent 5,798,266, US Patent 6,287,521, US Patent 6,689,073, US Patent 6,887,210, US Patent 7,128,877, and US Patent Application 20060030787.
Australia Australia: AU Patent 740,160, AU Patent 781,187 (alt), and AU Patent Application 2002227163.
Canada Canada: CA Patent 2,264,277 and CA Patent 2,427,967.
Europe Europe: EU 97938551.1 and one pending EU application.
Hong Kong Hong Kong: HK Patent 00100654.7 and HK application 03105927.4.
Japan Japan: JP Patent 4,050,612 and one pending JP divisional application.
PCT Application: PCT/US97/14863, Expired but National Phase entered, and EU 01993422.3 – Published.
We believe our patents will prevent laboratories other than Atossa from performing the cytology or biomarker services. Specifically, US patent 6,887,210 (the “’210 patent”) includes multiple claims to the patient NAF specimen kit vial, for example, to “a cytology vial having one or more air ports that communicate between an outer wall and inner lumen of the vial to form a gaseous connection between the lumen of the vial, the vacuum pump means, and the breast engaging member” and another claim to “a modified cytology vial.” The collection kits we will provide, which are covered by the ‘210 patent, will be sold under a limited “collection only” patent license, which permits the physician to collect the sample but does not provide a patent license for other uses of the vial, including transporting the sample or preparing cytology slides or conducting biomarker studies with the NAF sample. US patent 6,689,073, which will not be licensed with the kit sales, contains claims to the steps of transferring and processing samples to detect or quantify breast disease markers. The foreign patent counterparts contain similar claims.
The Company believes its patent estate could permit the Company to license to third party laboratories rights under the 6,689,073 patent to transfer, process, and make diagnoses from NAF samples and receive patent royalty revenue.
We have applied to the U.S. Patent and Trademark Office for registration of the use of the marks Atossa, MASCT, and Oxy-MASCT as trademarks and the pink, stylized Atossa Genetics logo as a service mark of the Company.
Very nice. I took a position here last week, finally getting around to posting. I'm very excited about Prospects here.
Patience LOL, when it breaks it will be a very pleasant awakening indeed.
Speaking of bottom plays, VOIS is at a nice all time low now, and it never fails to get run up after heavy accumulation down low.
Good Morning. Pick your favorite bottom play here, when they finish the pre-frontal-loads. They will either start front-loading by others in a higher range, or run on Pr and promotion.